Gland Pharma Ltd — Ertapenem Exporter Profile
Indian Pharmaceutical Exporter · #5 for Ertapenem · $800.0K export value · DGFT Verified
Gland Pharma Ltd is the #5 Indian exporter of Ertapenem with $800.0K in export value and 16 verified shipments. Gland Pharma Ltd holds a 2.1% market share in Ertapenem exports across 3 countries.
Gland Pharma Ltd — Ertapenem Export Profile: Buyers & Destinations
Where Does Gland Pharma Ltd Export Ertapenem?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.6M | 32 | 71.3% |
| COSTA RICA | $500.0K | 10 | 22.3% |
| DOMINICAN REPULIC | $50.0K | 1 | 2.2% |
| DOMINICAN REPUBLIC | $50.0K | 1 | 2.2% |
| CHINA | $43.9K | 1 | 2.0% |
Gland Pharma Ltd exports Ertapenem to 5 countries. The largest destination is UNITED STATES accounting for 71.3% of Gland Pharma Ltd's Ertapenem shipments, followed by COSTA RICA (22.3%) and DOMINICAN REPULIC (2.2%). These destinations reflect Gland Pharma Ltd's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ertapenem from Gland Pharma Ltd?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $850.0K | 17 |
| EVERSANA LIFE SERVICE SERVICES | UNITED STATES | $350.0K | 7 |
| LABORATORIOS STEIN S.A | COSTA RICA | $300.0K | 6 |
| CARDINAL HEALTH 105 INC. | UNITED STATES | $250.0K | 5 |
| LABORATORIES STEIN S.A | COSTA RICA | $200.0K | 4 |
| CARDINAL HEALTH | UNITED STATES | $150.0K | 3 |
| PHARMACEUTICAL TECHNOLOGY | DOMINICAN REPULIC | $100.0K | 2 |
| SHANGHAI FOSUN PHARMACEUTICAL INDUS | CHINA | $43.9K | 1 |
Gland Pharma Ltd supplies Ertapenem to 8 buyers globally. The largest buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by EVERSANA LIFE SERVICE SERVICES (UNITED STATES) and LABORATORIOS STEIN S.A (COSTA RICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ertapenem Export Value and How Much Does Gland Pharma Ltd Contribute?
India exported $35.1M worth of Ertapenem through 780 shipments from 54 suppliers to 46 countries, serving 137 buyers globally. Gland Pharma Ltd contributes $800.0K to this total, accounting for 2.1% of India's Ertapenem exports. Gland Pharma Ltd ships Ertapenem to 5 countries through 8 buyers.
What Is the Average Shipment Value for Gland Pharma Ltd's Ertapenem Exports?
Gland Pharma Ltd's average Ertapenem shipment value is $50.0K per consignment, based on 16 shipments totaling $800.0K. The largest destination is UNITED STATES (71.3% of Gland Pharma Ltd's Ertapenem exports).
How Does Gland Pharma Ltd Compare to Other Indian Ertapenem Exporters?
Gland Pharma Ltd ranks #5 among 54 Indian Ertapenem exporters with a 2.1% market share. The top 3 exporters are EUGIA PHARMA SPECIALITIES LIMITED ($26.9M), DR.REDDY'S LABORATORIES LTD ($1.8M), GLAND PHARMA LIMITED ($1.4M). Gland Pharma Ltd processed 16 shipments to 3 destination countries.
What Ertapenem Formulations Does Gland Pharma Ltd Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ERTAPENEM FOR INJECTION 1G/VIAL, 20ML VI | $550.0K | 11 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED) 1G | $250.0K | 5 |
| ERTAPENEM FOR INJECTION 1G/VIAL, 20ML VIAL | $250.0K | 5 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED)IG/ | $200.0K | 4 |
| ERTAPENEM FOR INJECTION 1G/VIAL 20ML VIAL | $200.0K | 4 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED) 1 | $150.0K | 3 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED)1G/ | $150.0K | 3 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED) 1G/VIAL,20ML VIAL | $150.0K | 3 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED)1G/VIAL, 20ML VIAL (7450 VIALS)NOS | $50.0K | 1 |
| ERTAPENEM FOR INJECTION (LYOPHILIZED) 1G/VIAL, 20ML VIALNOS | $50.0K | 1 |
Gland Pharma Ltd exports 15 distinct Ertapenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ERTAPENEM FOR INJECTION 1G/VIAL, 20ML VI with 11 shipments worth $550.0K.
Regulatory Requirements: Exporting Ertapenem to Key Markets
What Gland Pharma Ltd must comply with to export Ertapenem to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Gland Pharma Ltd Compare to Nearest Ertapenem Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | JODAS EXPOIM PRIVATE LIMITED | $850.0K | 17 | 1 | $50.0K |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $850.0K | 17 | 2 | $50.0K |
| 5 | GLAND PHARMA LTD ★ | $800.0K | 16 | 3 | $50.0K |
| 6 | DR REDDYS LABORATORIES LIMITED | $450.0K | 9 | 2 | $50.0K |
| 9 | DR REDDY S LABORATORIES LIMITED | $250.0K | 5 | 2 | $50.0K |
Gland Pharma Ltd ranks #5 among 54 Indian Ertapenem exporters. Average shipment value of $50.0K compared to the market average of $649.6K. The closest competitors by value are JODAS EXPOIM PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Ertapenem Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 248 | 31.8% |
| DELHI AIR | 185 | 23.7% |
| Delhi Air | 71 | 9.1% |
| HYDERABAD ACC (INHYD4) | 52 | 6.7% |
| HYDERABAD AIR | 33 | 4.2% |
| PETRAPOLE | 23 | 2.9% |
| SAHAR AIR | 21 | 2.7% |
| Dadri CGML | 19 | 2.4% |
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ertapenem — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ertapenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Gland Pharma Ltd matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 45 individual customs records matching Gland Pharma Ltd exporting Ertapenem, covering 15 formulations to 5 countries via 8 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 46+ countries, 137+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ertapenem Export Data from Gland Pharma Ltd
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Gland Pharma Ltd's Ertapenem exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Gland Pharma Ltd
Company Profile
0 products · $0 total trade · 0 categories
Ertapenem Stats
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Gland Pharma Ltd.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ertapenem. For current shipment-level data, contact TransData Nexus.